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Aberrant glycosylation, a common feature associated with malignancy, has been 
implicated in important events during cancer progression. Our understanding of the 
role of glycans in cancer has grown exponentially in the last few years, concurrent with 
important advances in glycomics and glycoproteomic technologies, paving the way for 
the validation of a number of glycan structures as potential glycobiomarkers. However, 
the molecular bases underlying cancer-associated glycan modifications are still far from 
understood. Glycans exhibit a natural heterogeneity, crucial for their diverse functional 
roles as specific carriers of biologically relevant information. This information is decoded 
by families of proteins named lectins, including sialic acid-binding immunoglobulin (Ig)-
like lectins (siglecs), C-type lectin receptors (CLRs), and galectins. Siglecs are primarily 
expressed on the surface of immune cells and differentially control innate and adaptive 
immune responses. Among CLRs, selectins are a family of cell adhesion molecules that 
mediate interactions between cancer cells and platelets, leukocytes, and endothelial 
cells, thus facilitating tumor cell invasion and metastasis. Galectins, a family of soluble 
proteins that bind β-galactoside-containing glycans, have been implicated in diverse 
events associated with cancer biology such as apoptosis, homotypic cell aggregation, 
angiogenesis, cell migration, and tumor-immune escape. Consequently, individual 
members of these lectin families have become promising targets for the design of novel 
anticancer therapies. During the past decade, a number of inhibitors of lectin–glycan 
interactions have been developed including small-molecule inhibitors, multivalent sac-
charide ligands, and more recently peptides and peptidomimetics have offered alterna-
tives for tackling tumor progression. In this article, we review the current status of the 
discovery and development of chemical lectin inhibitors and discuss novel strategies to 
limit cancer progression by targeting lectin–glycan interactions.
Keywords: glycans, cancer, siglecs, C-type lectins, selectins, galectins
2Cagnoni et al. Inhibition of Lectin–Glycan Interactions in Cancer
Frontiers in Oncology | www.frontiersin.org May 2016 | Volume 6 | Article 109
iNTRODUCTiON: DeCiPHeRiNG THe 
“GLYCO-CODe” iN CANCeR
Cancer is a leading cause of death worldwide and represents one 
of the biggest challenges faced by medicine. Novel biological 
therapies such as tumor-antigen targeted vaccines (1, 2) and 
immune checkpoint blockade [i.e., monoclonal antibody (mAb)-
based therapies targeting cytotoxic T-lymphocyte antigen 4 
(CTLA-4) or programed cell death protein-1 (PD-1) (3–5)] 
have been designed to target specific determinants expressed by 
different tumor types and their associated stroma and immune 
compartments. However, due to the complexity of the tumor 
microenvironment (TME) and the intrinsic or acquired resist-
ance mechanisms, only certain types of cancers can be effectively 
treated by these therapies (3–5). Furthermore, variable responses 
in patients with a similar malignancy reflect inherent heteroge-
neity among different tumor types (5). As technology advances, 
genomics studies have unveiled specific genetic signatures, which 
enabled tailored treatments and personalized cancer therapy to 
move a step closer to fruition. In time, other high-throughput 
technologies have emerged to expand personalized medicine 
beyond genomics, including proteomics and more recently, 
glycomics (6).
Glycosylation is the most abundant posttranslational modi-
fication: all cell surface and secreted glycoproteins must travel 
through the endoplasmic reticulum and the Golgi compartments, 
where addition of carbohydrates take place. The structure and 
nature of glycans strongly influence various functional aspects 
of glycoproteins such as cellular localization, turnover, protein 
quality control, and receptor–ligand interactions. The structural 
diversity of glycans, a key aspect that governs their role as infor-
mation carriers, results from the concerted action of a number 
of glycosyltransferases and/or glycosylhydrolases that build 
and remodel their structure, generating a variety of glycoforms 
for a specific peptide sequence and allowing both cell-type and 
protein-specific glycan expression patterns (7, 8). Taking into 
consideration the ubiquitous presence of glycoconjugates on the 
cell surface, the fact that certain human diseases (including can-
cer) display altered glycan processing pathways is not surprising 
to glycobiologists (9, 10).
During the last decades, and as a result of advances in gly-
comics and glycoproteomics technologies, aberrant cell sur-
face glycosylation has been considered an important hallmark 
of cellular oncogenesis and tumor progression. Simultaneous 
alterations of the overall glycome were identified in several 
types of cancer, where a differential glycan profile could be 
found not only in tumor cells themselves and the associated 
microenvironment (stromal fibroblasts, endothelial cells, and 
immune infiltrating cells) but also in serum glycoproteins 
(i.e., acute phase proteins), revealing potential glycobiomark-
ers of malignancy (11–13). It is now well established that 
aberrant glycosylation can promote tumor cell invasion and 
metastasis, as these processes involve cell detachment, intra-
vasation, transport, attachment, extravasation, and angio-
genesis (14). A long-standing and still unresolved question is 
whether aberrant glycosylation is a cause or a consequence of 
tumorigenesis.
Aberrant glycosylation in cancer is usually associated with 
poor prognosis, and may be present in different glycoconjugates, 
not only in N- and O-glycans on cell surface glycoproteins (15) 
but also in glycolipids and glycosaminoglycans (GAGs) (13, 16). 
These altered structures constitute the so-called tumor-associated 
cancer antigens (TACAs; Figure 1), and implicate not only the 
under- or overexpression of naturally occurring glycans but also 
the neo-expression of others. Glycan alterations vary depend-
ing on the type of cancer, but for N-glycans, they can include 
differential expression of blood group Lewis-related antigens 
such as Lewis X (LeX), Lewis Y (LeY), sialyl Lewis X (SLeX), and 
sialyl Lewis A (SLeA), increased synthesis of polylactosamine 
chains, increased β(1 → 6) branching of N-linked glycans, core 
α(1 → 6)-fucosylation, outer arm α(1 → 2)- and α(1 → 3)-fuco-
sylation, and changes in sialylation, among others (11, 17, 18) 
(Figure 1A). For O-glycans and glycolipids, expression of TACA 
include mucin-related (O-linked) GalNAc (Tn), sialyl Tn (STn), 
Thomsen–Friedenreich antigen (Tf), polysialic acid (PSA), gly-
cosphingolipid Globo-H, and gangliosides GM2 and GD2/GD3 
(2, 9, 14, 19, 20) (Figures 1B,C).
It has been clearly demonstrated that these changes in glyco-
sylation are dependent on biochemical factors such as availability 
of nucleotide sugar pools (activated donors for glycan biosyn-
thesis), and differential expression of certain glycosyltransferases 
(17). As examples of important glycosylatransferases involved 
in O-glycan aberrant biosynthesis, ppGalNAc6 (GALNT6, 
one of the UDP-N-acetyl-d-galactosamine: polypeptide 
N-acetylgalactosaminyltransferases responsible for the initiation 
of mucin-type O-glycosylation) is upregulated in breast cancer 
(22) and has been also postulated as a potential marker associated 
with venous invasion in gastric carcinoma (23). On the other hand, 
GALNT9, another member of this family, has been described as 
a prognostic marker in neuroblastoma (24). In prostate cancer, 
overexpression of GCNT1 [β(1 → 6)-N-acetylglucosaminyltrans
ferase, involved in core 2 O-glycan biosynthesis] was associated 
with higher levels of core 2 O-SLex in prostate specific antigen 
(PSA) (25). Regarding N-glycans, bisecting GlcNAc has been 
identified as a hallmark of epithelial ovarian cancer and mannosyl 
β(1 → 4)-glycoprotein β(1 → 4)-N-acetylglucosaminyltransfera
se (MGAT3), the glycosyltransferase involved in its biosynthesis, 
showed a clear upregulation in ovarian cancer (26). Finally, Wang 
et al. described an upregulation of Fut8, a fucosyltransferase that 
decorates the N-glycan core, in hepatocellular carcinoma (HCC), 
and core fucosylation was proposed as a prognostic marker as 
well as a therapeutic target for HCC (27). The role of N-glycans 
and O-glycans in cancer has been thoroughly reviewed in previ-
ous publications (17, 28, 29).
Even though there is abundant evidence on the important 
role of altered expression of glycosyltransferases in tumor cells, 
the regulation of glycan-related pathways is still far from clear. 
In the last few years, studies describing the influence of DNA 
methylation (26, 30) as well as cytokine levels (31) have shed 
light on these issues. Finally, a recent article describing the 
mutational landscape of aberrant glycosylation in colon cancer 
has shown specific mutations associated to glycosyltransferases in 
patients, particularly in B3GNT2, B4GALT2, and ST6GALNAc2. 
These significant findings indicate that functionally deleterious 
FiGURe 1 | Common alterations observed in cancer in (A) N-glycosylation and (B) O-glycosylation. Green and red arrows represent increased and 
decreased expression of glycan structures, respectively. (C) Principal tumor-associated carbohydrate antigens (TACAs). In all cases, glycans are represented using a 
combination of the Oxford (21) and the Consortium for Functional Glycomics formats (http://www.functionalglycomics.org/).
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mutations in glycosyltransferase genes in part underlie aberrant 
glycosylation and contribute to the pathogenesis of molecular 
subsets of colon and other gastrointestinal malignancies (32).
These glycosylation changes, complex as they are, trigger dif-
ferent biological processes via interaction with an evolutionarily 
divergent family of glycan-binding proteins or lectins. Lessons 
learned from knockout and transgenic models in physiologic 
and pathologic settings revealed major roles for lectin–glycan 
interactions in immune cell homeostasis, controlling regulatory 
cell programs, and activating tolerogenic circuits that orchestrate 
tumor-immune escape mechanisms (33, 34). In this review, we 
focus on therapeutic strategies, based on chemical inhibition 
of three different lectin families, namely sialic acid-binding 
immunoglobulin (Ig)-like lectins (siglecs), C-type lectin recep-
tors (CLRs), and galectins, which play relevant roles in cancer 
(Figure 2).
Siglecs and immune evasion in Cancer
Siglecs, also known as the I-type lectin family, constitute a 
family of sialic acid binding Ig domain-containing lectins that 
are mainly found on cells of the immune and hematopoietic 
system (35) (Figure  2). From a structural viewpoint, siglecs 
are transmembrane type I receptors bearing 2–16 extracellular 
C2-set Ig domains, with an extracellular N-terminal V-set Ig 
(Ig-V) domain responsible for the binding of sialoside ligands 
(36), a single transmembrane domain, and varying lengths of 
FiGURe 2 | Schematic representation of three lectin families: (A) siglecs, (B) C-type lectins, and (C) galectins.
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cytosolic tails (37) (Figure  2A). Siglecs are typically classified 
into two functionally diverse subsets. The most distantly inter-
related group  (25–30% sequence identity) includes Siglec-1 
(Sialoadhesin, Sn), -2 (CD22), -4 [myelin-associated glycoprotein 
(MAG)], and -15. The second group represents the rapidly evolv-
ing CD33-related Siglecs, which have high homology to CD33 
in their extracellular domains (50–85% identity) and comprises 
Siglec-3 (CD33), -5, -6, -7, -8, -9, -10, -11, and -14 (35, 37, 38).
FiGURe 3 | The role of siglecs in immune evasion mechanisms. (A) Siglec-7 is expressed predominantly on NK cells and inhibits NK cell cytotoxicity toward 
target cells overexpressing the α(2 → 8)-disialic acid-bearing ganglioside, GD3. (B) Siglec-15 recognizes the tumor sialyl-Tn (sTn) antigen and transduces an 
intracellular signal leading to enhance TGF-β secretion and polarization toward an M2-like macrophage profile, which contributes to tumor progression.
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Siglecs are primarily expressed in B cells, macrophages, 
dendritic cells (DCs), and eosinophils and have been implicated 
in both innate and adaptive immunity. They play important 
roles in host–pathogen interactions, cell–cell communication, 
and regulation of immune tolerance (39), maintaining immune 
homeostasis and regulating inflammatory processes (37). With 
respect to innate immunity, Siglecs have been involved in patho-
gen internalization and immune evasion, attenuation of damage-
associated molecular pattern (DAMP)-mediated inflammation, 
and inhibition of natural killer (NK) cell function. In adaptive 
immunity, they act as modulators of T-cell activation and polari-
zation as well as regulators of B cells and plasmacytoid DCs (38).
Many siglecs have been studied as potential targets for the design 
of therapeutic agents for the treatment of inflammatory, autoim-
mune, allergic, and infectious diseases (35). Even though changes 
in sialylation may modulate tumor cell invasion or metastasis, 
the involvement of siglecs in tumor immunity is currently being 
explored. For example, Siglec-2 (CD22) has been implicated in 
B-cell activation in non-Hodgkin Lymphoma (40), and Siglec-7 
has been shown to exert a pivotal role in tumor escape by inacti-
vation of NK cells (41) (Figure 3A). Siglec-3 (CD33) is expressed 
on malignant blast cells in 85–90% of Acute Myeloid Leukemia 
cases, while is absent on normal hematopoietic pluripotent stem 
cells (42). Takamiya et al. reported that Siglec-15, which preferen-
tially recognizes sialyl-Tn antigen (Figure 1), induced a M2-like 
immunosuppressive macrophage phenotype and upregulated 
TGF-β secretion in human monocytic leukemia cells and human 
lung carcinoma cells (43) (Figure 3B). Furthermore, interactions 
between Siglec-4a (MAG) and the mucin MUC1 enhanced 
adhesion of pancreatic cells and stimulated pancreatic cancer cell 
perineural invasion (44). Other siglecs have been correlated with 
tumor progression, such as Siglec-9, involved in tumor-immune 
evasion, and Siglec-12, which was found to be overexpressed on 
human prostate epithelial carcinomas (45).
Role of Selectins in Metastasis and  
Tumor-Associated inflammation
C-type lectins comprise a diverse family of calcium-dependent 
glycan-binding proteins that play essential immunological roles 
as adhesion and signaling receptors in inflammation, tumor 
progression, and viral infections (46). This lectin family is 
classified into 17 different subgroups depending on their C-type 
lectin domains and their structures. Some representative subsets 
are collectins, endocytic receptors [Mannose Receptor (MR), 
Dec-205], DC receptors [dendritic-cell specific intracellular 
adhesion molecule 3-grabbing non-integrin (DC-SIGN)], mac-
rophage galactose-binding lectin (MGL), Langerin, and selectins 
(L-Selectin, P-Selectin, and E-Selectin) (Figure 2B).
Given their biological and clinical relevance, we will focus 
here on Selectins, C-type transmembrane lectins that mediate 
leukocyte trafficking and specific adhesive interactions of leuko-
cytes, platelets, and endothelial cells with tumor cells (47). These 
lectins are present on endothelial cells (E-Selectin), leukocytes 
(L-Selectin), and platelets (P-Selectin) (46), and preferentially 
bind glycans containing SLeX and SLeA glycoepitopes (Figure 1), 
which are abundantly expressed in several tumor types. In the 
TME, selectins are functionally relevant in the context of leuko-
cyte recruitment, tumor-promoting inflammation, and acquisi-
tion of metastatic potential (36) (Figure 4).
P-Selectin (CD62P) is involved in tumor growth and metas-
tasis, as it mediates interactions between activated platelets 
and cancer cells contributing to tumorigenesis (47). E-Selectin 
(CD62E) also play major roles in cancer cell adhesiveness at 
different events of the metastatic cascade, promoting tumor cell 
extravasation (48). Finally, L-Selectin (CD62L), constitutively 
expressed on leukocytes, regulates tumor–leukocyte interactions 
and promotes cell adhesion and hematogenous metastasis by 
favoring emboli formation (49).
Because of their critical involvement in cancer metastasis, sev-
eral research groups have developed therapeutic strategies based 
on disruption of selectin–glycan interactions with the ultimate 
goal of controlling inflammation and metastasis (48).
The Galectin–Glycan Axis in Cancer 
Development
Galectins, a family of highly conserved glycan-binding soluble 
lectins, are defined by a conserved carbohydrate recognition 
domain (CRD) and a common structural fold (50). Based on 
structural features, mammalian galectins have been classified 
into three types: prototype galectins (Gal-1, -2, -5, -7, -10, -11, 
-13, -14, and -15, containing one CRD and existing as monomers 
or dimerizing through non-covalent interactions), tandem 
FiGURe 4 | Selectins in cancer biology. Selectins play different roles in tumor biology including modulation of platelet–cancer cell interactions (P-selectin), 
promotion of tumor cell adhesiveness, extravasation and metastasis (E-selectin), and leukocyte trafficking and hematogenous metastasis (L-selectin).
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repeat-type galectins (Gal-4, -6, -8, -9, and -12), which exist as 
bivalent galectins containing two different CRDs connected by a 
linker peptide, and finally, Gal-3, the only chimera-type member 
of the galectin family (Figure 2). Their distribution in mammalian 
tissues is diverse. While Gal-1 and -3 are detected ubiquitously, 
other galectins are more specifically located, such as Gal-2 and 
-4, which are preferentially found in the gastrointestinal tract 
(51, 52), Gal-7 is highly abundant in the skin (53), Gal-10 in 
eosinophils (54), and Gal-12 in adipose tissue (55, 56).
The ability of galectins to modulate different events in tumo-
rigenesis and metastasis makes them attractive targets for cancer 
therapy (57, 58), controlling malignant transformation (59), 
apoptosis (60), cell-cycle progression (61), angiogenesis (62, 
63), tumor metastasis (64, 65), and tumor immune escape (66). 
Galectins contribute to immune tolerance and escape through 
apoptosis of effector T cells (67), regulation of clonal expansion, 
function of regulatory T cells (Tregs) (64), and control of cytokine 
secretion (68). Expression levels for some galectins also change 
during malignant transformation, confirming their essential roles 
in cancer progression (69). Among the galectin family members, 
in this review, we will focus on Gal-1 and Gal-3, the two most 
extensively studied galectins, which have key roles during cancer 
progression.
Gal-1, abundantly secreted by almost all malignant tumor 
cells, has been characterized as a major promoter of an immu-
nosuppressive protumorigenic microenvironment (67). This 
lectin induces selective apoptosis of TH1 and TH17 effector T 
cells, without affecting TH2 cells due to differential sialylation of 
cell surface glycoproteins (67, 70) (Figure 5). In recent years, the 
immunosuppressive activity of Gal-1 has also been extended to 
differentiation and expansion of CD4+CD25+Foxp3+ Tregs (64) 
and, similarly to other galectins, controls cell surface retention 
and signaling thresholds of a number of glycosylated receptors. 
However, its immunoregulatory activity is not limited to T cell 
populations: Gal-1 also promotes differentiation of tolerogenic 
dendritic cells (tDCs) (71) and controls tissue emigration 
of immunogenic, but not tDCs (72). The tolerogenic effects 
induced by this lectin have been substantiated by the work of 
FiGURe 5 | Major roles of Gal-1 and Gal-3 during cancer progression. (A) Intracellular Gal-1 triggers activation of the H-Ras/ERK cascade leading to 
malignant transformation. (B) Gal-1 promotes adhesion of tumor cells to extracellular matrix and endothelial cells, critical steps during early stages of tumor invasion 
and metastasis. (C) Gal-1 induces tumor angiogenesis by engaging key proangiogenic pathways including VEGF-like signaling. (D) Resistance to apoptosis is 
essential for cancer cell survival and plays a role in tumor progression. Gal-3 suppresses apoptosis induced by cisplatin, nitric oxide (NO), or radiation, through 
interactions with P-gp and Na+/K+-ATPase, thus promoting tumor cell survival. (e) Gal-1 selectively deletes TH1 and TH17 cells and (G) promotes the differentiation 
of tolerogenic DCs (tDCs). (F) Gal-1 promotes expansion of CD4+CD25+Foxp3+ regulatory T cells (Tregs) and amplifies their immunosuppressive activity. (H) Gal-3 
induces anergy of CD8+ T cells by distancing the TCR from CD8 molecules. (i) Gal-3 impairs NK cell function by inhibiting the interactions between the heavily 
O-glycosylated tumor-derived MICA and the NK cell activating receptor NKG2D.
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Kuo and colleagues, who found that Gal-1-induced tDCs in lung 
cancer also favored the induction of Tregs (73). Furthermore, in 
addition to its immune inhibitory effects, Gal-1 can also favor 
tumor development and progression through promotion of 
tumor angiogenesis, favoring vascular endothelial growth factor 
(VEGF) signaling, and promoting endothelial cell proliferation, 
adhesion, migration, and resistance to apoptosis (34, 74). Finally, 
Gal-1 has been reported to contribute to heterotypic adhesion of 
tumor cells to extracellular matrix and endothelial cells, critical 
steps during the early stages of tumor invasion and metastasis 
(74, 75). Finally, within the intracellular compartment, Gal-1 
also interacts with oncogenic H-Ras–guanosine triphosphate 
(H-Ras–GTP) through its farnesyl group, enhancing H-Ras-
mediated cell transformation through ERK1/2 signaling (76) 
(Figure 5).
Gal-3, another member of the family, has shown prominent 
protumorigenic effects in a multiplicity of tumors. This multi-
functional protein has demonstrated different effects depending 
on its subcellular localization (77) (Figure 5). A pioneer work by 
Raz et  al. reported a correlation between higher Gal-3 expres-
sion and increase incidence of experimental lung metastases in 
mouse models (78). Since then, compelling evidence has impli-
cated Gal-3 expression with different aspects of cancer biology 
including cell adhesion, migration, angiogenesis, and immune 
escape (79, 80).
Thomsen–Friedenreich glycoantigen (Tf; Figure  1) is 
expressed in up to 90% of human carcinomas (81) and is a major 
cancer cell surface carbohydrate ligand for Gal-3. Similarly to 
Gal-1, Gal-3 signaling contributes to tilt the balance toward 
immunosuppressive TMEs by interacting with specific glycans, 
8Cagnoni et al. Inhibition of Lectin–Glycan Interactions in Cancer
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and impairing antitumor responses. In this regard, Gal-3 has 
been shown to promote anergy of tumor infiltrating lymphocytes 
(TILs) (82). Furthermore, Tsuboi et al. described a new mecha-
nism of tumor escape involving Gal-3 and NK cells in bladder 
cancer (83); the authors demonstrated that overexpression of 
core 2 β(1→6)-N-acetylglucosaminyl transferase 1 (C2GnT1), 
a glycosyltransferase responsible of generating branched core-2 
O-glycans that can be elongated with poly-N-acetyllactosamine 
(LacNAc) sequences, negatively controls the activity of tumor-
associated major histocompatibility complex class I-related 
chain A (MICA). Interactions between polyLacNAc and Gal-3 
reduced the affinity of MICA to the NK cell receptor NKG2D, 
thereby impairing NK cell activation and their antitumor activity 
[(71) Figure  5]. However, Gal-3 not only assists tumor escape 
by inhibiting immune responses; it also promotes tumor cell 
survival by hampering drug-induced apoptosis by cisplatin, nitric 
oxide (NO) or radiation, through phosphorylation, translocation, 
and regulation of survival signaling pathways (84, 85) (Figure 5). 
The mechanisms underlying Gal-3 protection of drug-induced 
apoptosis has recently been reported by Harazono et  al. (86, 
87), who showed that interaction of this lectin with Na+/K+-
ATPase activated SRC tyrosine kinase, subsequently inducing 
phosphorylation of P-glycoprotein (P-gp) and enhancing its 
ATPase activity. These effects contribute to decrease sensitivity to 
doxorubicin-mediated cell death (72, 73).
STRUCTURe, FUNCTiON, AND CLiNiCAL 
PROSPeCTS OF LeCTiN-iNHiBiTORY 
ANTiTUMOR CHeMiCAL AGeNTS
Antitumor and Antimetastastic Agents 
Targeting Selectins
A variety of approaches have been designed to tackle selectin-
mediated inflammation and metastasis through chemical inhibi-
tion. As a result, sulfated polysaccharides, modified glycans, and 
glycopeptides have been postulated as pharmacological selectin 
inhibitors (Table 1).
Sulfated Oligosaccharides
Heparin (1, Table  1), a highly sulfated polysaccharide from 
the GAG family, is composed of a repetitive disaccharide unit 
containing glucosamine and glucuronic/iduronic acid residues 
with a high degree of sulfation (95). Heparins and its derivatives, 
traditionally used as anticoagulants, have recently emerged as 
attractive compounds for selectin inhibition showing promising 
antimetastatic activity through disruption of P- and L-selectin-
mediated adhesion of tumor cells (96). In an attempt to reduce the 
anticoagulant activity of heparin and enhance its affinity toward 
selectins, different chemical modifications such as N-acetylation, 
succinylation, O-desulfation, and reduction have been performed 
(97, 98). Heparins of different molecular weight have been suc-
cessfully tested in tumor models such as melanoma, sarcoma, 
breast, and colon adenocarcinoma demonstrating inhibitory 
effects on tumor metastasis. However, they had limited effects 
on tumor growth, showing that heparin mediates interactions of 
tumor cells with host cells and the extracellular matrix during 
the metastatic process (99). Heparin and its derivatives have been 
tested in numerous clinical trials, but mostly as anticoagulant 
agents for prevention of cancer-related thrombosis (100).
Other negatively charged polysaccharides have also been 
evaluated as selectin inhibitors. Dermatan sulfate (2, Table  1), 
a sulfated polysaccharide bearing a [→4)-IdoA(2S)-β(1  →   
3)-GalNAc-β-(1→] repetitive unit, has shown to be an effective 
P-selectin inhibitor in vitro for colon carcinoma and melanoma 
in experimental models (89). 6-O-Sulfated chitosan (3, Table 1), 
a modified linear β-(1 → 4)-glucosamine polysaccharide, has also 
demonstrated the ability to reduce interactions of P-selectin with 
melanoma cells in vitro (90).
Taken together, these findings suggest that inhibition of selec-
tin–glycan interactions by charged polysaccharidic agents could 
become an alternative therapy for inhibition of tumor metastasis. 
However, further analyses are necessary not only to unravel the 
mechanisms underlying the pharmacological activity of these 
compounds but also to reduce the risk of heparin-induced 
anticoagulant-related side effects.
Glycomimetics
As selectins preferentially bind to sulfated or fucosylated 
oligosaccharides such as SLeX or SLeA (Figure  1), Lewis-type 
glycomimetic analogs emerged as interesting decoys for disrup-
tion of selectin-mediated processes. Non-reductive disaccharide 
Gal-α-(1 →  1)-β-Man became a promising building block for 
SLeX glycomimetics, and a number of research groups have 
explored fluorinated C-glycosyl analogs (4, Table 1) in an attempt 
to improve the pharmacokinetics of these ligands (91, 101). On a 
different approach, Shodai et al. designed NMSO3 (5, Table 1), a 
sulfated derivative of sialic acid, which demonstrated to be a good 
inhibitor of P-selectin-mediated tumor cell adhesion (92).
Glycopeptides
Besides carbohydrates, glycopeptides were also evaluated as 
selectin blockers. Flexible difluorinated C-mannopeptides (6, 
Table 1) were synthesized and tested as E- and P-selectin inhibi-
tors, exhibiting moderate binding affinities (93). Starting from 
SLeX, Filser et al. designed high-affinity synthetic glycopeptides 
for E-selectin inhibition, bearing a peptide sequence from the 
natural ligand E-selectin ligand-1 (ESL-1) and replacing the sialic 
acid with a cyclohexyl moiety (7, Table  1). These compounds 
confirmed that the peptide moiety was essential for selectin bind-
ing and exhibited encouraging IC50 values in the low micromolar 
range (94). However, no experiments have yet corroborated their 
efficacy in vitro or in vivo.
Siglec inhibition in Cancer Treatment: 
Sialic Acid Derivatives
Compared to the advances made for selectins or galectins, the role 
of siglecs during cancer progression has not been studied in such 
detail. Thus, there have been fewer reports on siglec inhibitors 
as anticancer agents. Promising approaches reported in literature 
include C4- and C9-modified sialic acid derivatives (Figure 6). 
Siglec-7, which belongs to the CD33-related siglec type, pref-
erentially binds internally branched α(2 → 6) sialic acid and is 
TABLe 1 | Structure and clinical applications of different anti-selectin agents described in this review.
Type Name N° Structure Tumor type tested Reference
Heparin 
derivatives
Heparin sulfate 1 Human sarcoma, melanoma, 
and colon carcinoma
(88)
Dermatan sulfate 2 Colon carcinoma and melanoma (89)
6-O-sulfated chitosan 3 Human melanoma (90)
SLeX 
glyco-mimetics
Gal-α-(1 → 1)-β-Man 
C-fluorinated analogs
4 (91)
NMSO3 5 Human promyelocytic leukemia (92)
Glyco-peptides Fluorinated C-manno-peptides 6 (93)
SLeX-glyco-peptide 7 (94)
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primarily expressed on NK cells. This lectin has been reported 
to favorably interact with melanoma or neuroblastoma cancer 
cells that overexpress GD3, an α(2 →  8) disialic acid-bearing 
ganglioside, thus inhibiting NK cell cytotoxicity as an immune 
evasion mechanism (102). In an attempt to disrupt Siglec-7–GD3 
interactions as a potential cancer therapeutic strategy, Attrill et al. 
described the design of sialic acid derivatives as inhibitors of 
Siglec-7 signaling (103). One of these ligands, oxamido-Neu5Ac 
[8, Table 2, methyl α-9-(amino-oxalyl-amino)-9-deoxy-Neu5Ac] 
exhibited a twofold decrease in the IC50 value (1.6  mM) for 
inhibition of Siglec-7 in vitro, compared to the canonical ligand 
methyl-α-Neu5Ac (>3.0 mM) (103).
Another interesting approach was reported by Kelm et al. 
who described the synthesis of sialic acid derivatives as 
high-affinity inhibitors of Siglec-2 (106). CD22 or Siglec-2 
is an antigen widely expressed on normal and malignant 
B cells and plays a primary role in B-cell activation. Thus, 
it has become an interesting target for the treatment of 
autoimmune diseases and B-cell derived non-Hodgkin’s 
Lymphoma (40). In 2002, Kelm et  al. reported the synthesis 
of a C9-modified Neu5Ac, namely methyl-α-9-N-(biphenyl-4- 
carbonyl)-amino-9-deoxy-Neu5Ac (BPC-Neu5Ac, 9, Table 2), 
which exhibited a >200-fold relative inhibitory potency (rIP) 
for human CD22 than Me-α-Neu5Ac (104). More recently, 
TABLe 2 | Anti-siglec agents described in this review.
Name N° Structure Tumor type tested Reference
Oxamido-Neu5Ac 8 (103)
BPC-Neu5Ac 9 Non-Hodgkin’s lymphoma (104)
BPC-Neu5Ac-Dox liposome 10 Non-Hodgkin’s lymphoma (105)
9-BPC-4-mNPC-Neu5Ac 11 (106)
FiGURe 6 | Modifications of neuraminic acid leading to high-affinity 
siglec blockers. Green circles denote the main positions modified in search 
of high-binding affinity and selective siglec inhibitors.
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Paulson and colleagues used this potent Siglec-2 inhibitor 
for the design of doxorubicin-loaded liposomal nanoparticles 
bearing BPC-Neu5Ac (9, Table  2) ligands to target B cell 
lymphoma (105). The CD22-targeted BPC-Neu5Ac-Dox 
liposomes (10, Table  2) provided a significant increase in 
survival rates when injected into a xenograft model of human 
B-cell lymphoma. Interestingly, this delivery strategy exhibited 
cytotoxic effects toward malignant B cells in patients with 
hairy cell leukemia, marginal zone lymphoma, and chronic 
lymphocytic leukemia. In 2013, Kelm et al. presented a further 
optimized novel glycan inhibitor with modifications on both 
Neu5Ac C4 and C9 positions (106). This compound, methyl 
9-biphenylcarboxamido-4-m-nitrophenylcarboxamido-
4,9-dideoxy Neu5Ac (9-BPC-4-mNPC-Neu5Ac, 11, Table  2) 
presented a 14-fold decrease in the IC50 value toward Siglec-2, 
thus emerging as a promising lead agent, although its activity 
has not yet been tested in vitro or in vivo.
Therapeutic Strategies Targeting  
Galectin–Glycan interactions in the TMe
Given the key protumorigenic, prometastatic, and immunosup-
pressive activities of galectins and their roles in tumor resistance 
to antiangiogenic therapies, important efforts have been made in 
the design of high-binding affinity specific inhibitors. Here, we 
describe a number of successful strategies to chemically disrupt 
galectin–ligand interactions and discuss advantages, limitations, 
and obstacles in their translation to clinical settings.
Low-Molecular Weight Inhibitors
A First Step: β-Galactoside Ligands
Since galectins share the structurally conserved CRD that defines 
their natural ligands, the initial approach was the design of 
β-galactoside inhibitors targeting the carbohydrate-binding site 
(107). Specific modifications of the galactose-based structures 
have led to the design of good inhibitors with dissociation con-
stants in the micromolar range (20–300 μM) (108, 109). However, 
the diverse chemical modifications tested on this monosaccharide 
did not achieve enough improvement on galectin affinity, and in 
consequence, galactose-based monosaccharide inhibitors have 
not been tested in cultured cells or in vivo.
The second approach for the design of galectin inhibitors 
was the use of chemically modified natural galectin ligands, 
such as the disaccharides lactose (Lac) or N-acetyllactosamine 
(LacNAc). Ingrassia et  al. reported an unspecific lactosylated 
steroid (12, Table 3) that induced increased survival rates when 
administered in experimental models of mouse lymphoma and 
human glioblastoma (110). Furthermore, Iurisci et al. reported 
the use of allyl-lactoside (13, Table  3) as ligand of Gal-1 and 
TABLe 3 | Structure and applications of different anti-galectin agents described in this review.
Type Name N° Structure Tumor type tested Reference
Low-molecular 
weight inhibitors
Lactosylated steroid 12 Mouse models of mouse 
lymphoma and human 
gliblastoma
(110)
Allyl lactoside 13 Human melanoma and 
small cell lung cancer 
cells
(111)
Thiodigalactoside (TDG) 14 Murine lung metastasis (112)
3,3′-di-(3-metoxibenzamido)-
thiodigalactoside
15 (113)
3,3′-ditriazolyl thiodigalactoside 16 (113)
Td131_1 17 Papillary thyroid cancer (114)
Talosamide 18 (115)
Glycoamines Lactulose-l-leucine (Lac-l-Leu) 19 Human breast 
carcinoma, prostate 
cancer
(116–118)
N-lactulose-
octamethylenediamine (LDO)
20 Melanoma and lung 
carcinoma
(119)
N, N′-dilactulose-
octamethylenediamine (D-LDO)
21
N, N′-dilactulose-
dodecamethylenediamine 
(D-LDD)
22
(Continued)
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Type Name N° Structure Tumor type tested Reference
Polysaccharide-
based 
compounds
Pectin-derived 
compounds
Pectasol-C 23 Prostate and human 
breast cancer
(120–124)
GCS-100 24 Myeloma and leukemia (125, 126)
GR-MD-02 25 Melanoma (127)
Galactomannan-
derived compound
GM-CT-01 
(DAVANAT)
26 Colon cancer (128)
Peptides G3-A9 27 PQNSKIPGPTFLDPH Breast carcinoma 
metastasis, prostate 
cancer
(129, 130)
G3-C12 28 ANTPCGPYTHDCPVKR
Anginex 29 Ovarian carcinoma (131)
Peptidomimetics 6DBF7 30 Ovarian carcinoma (132)
OTX008 31 Ovarian carcinoma and 
murine melanoma and 
glioblastoma
(133, 134)
TABLe 3 | Continued
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Gal-3, inhibiting homotypic cell aggregation in human melanoma 
cells, and promoting apoptosis of small cell lung carcinoma cells 
(111). Although Lac and LacNAc are more promising scaffolds 
than galactose for the design of galectin inhibitors since both 
disaccharides present higher binding affinity than galactose 
(KD ≈ 90–500 μM), they are both sensitive to enzymatic hydroly-
sis by glycosidases.
Chemical modifications in O2 and O3 of the galactose residue 
in lactose (named O2′ and O3′; Figure 7) afforded novel struc-
tures with anticancer biological activities. The Nilsson group 
explored galactose O3′ modifications for Gal-3 binding, showing 
that lactose O3′ modification with aromatic groups led to active 
Gal-3 inhibitors with binding affinities as low as 300–600 nM, due 
to additional favorable cation–π interactions with a conserved 
arginine residue, Arg-144, in the carbohydrate-binding site (113). 
However, these Gal-3 blockers showed affinities in the micromo-
lar/low millimolar range (100–1000 μM) when tested in vitro.
In order to overcome the poor bioavailability of lactose 
derivatives, thiosugars, and in particular, thiodigalactoside 
(TDG; 14, Table 3) have emerged as interesting building blocks 
for the design of potent galectin inhibitors, although with low 
selectivity (135, 136). Ito et al. demonstrated that administration 
of TDG significantly reduced tumor progression and metastasis 
via Gal-1 inhibition, using murine models of breast and colon 
adenocarcinoma (112). Moreover, intratumoral injection of TDG 
raised the level TILs and reduced tumor growth in models of B16 
melanoma as well as 4T1 orthotopic breast cancer models (137). 
Symmetrical modifications of TDG at O3 and O3′ positions led 
to increased galectin-binding affinities, affording the most potent 
Gal-3 inhibitors in vitro reported to date (136), with KD values 
FiGURe 7 | Mono and disaccharides as building blocks to design 
galectin inhibitors. Structures of galactose (Gal), talose (Tal), N-
acetyllactosamine (LacNAc), and thiodigalactoside (TDG). Green circles 
denote critical modified positions in search for high-binding affinity and 
selective galectin inhibitors.
13
Cagnoni et al. Inhibition of Lectin–Glycan Interactions in Cancer
Frontiers in Oncology | www.frontiersin.org May 2016 | Volume 6 | Article 109
as low as 29 nM (3,3′-ditriazolyl thiodigalactoside, 15, Table 3) 
and 50 nM (3,3′-di-3-metoxibenzamido thiodigalactoside) (16, 
Table 3). In spite of their promising biochemical performance, 
in  vivo experiments were not as encouraging. For instance 
Td131_1 (17, Table  3), an ester-modified TDG derivative, was 
evaluated as a Gal-3 inhibitor in papillary thyroid cancer. This 
compound showed concomitant increased apoptosis of cancer 
cells, although requiring concentrations up to 1000 times than 
the KD value (114).
Changing Stereochemistry for Enhanced Selectivity:  
Talose-Based Ligands
Carbohydrates are characterized for containing multiple stereo-
centers, and many stereoisomers are possible including enanti-
omers and diastereoisomers. Talose (a C-2 epimer of galactose; 
Figure 7) provides an axially disposed O2 and additional pro-
tein–ligand interactions, potentially making talose-based inhibi-
tors more selective than galactose-based ones. This approach was 
taken by Nilsson and collaborators, who created a new family of 
synthetic talosides that showed affinity and selectivity toward 
Gal-4 (C-terminal CRD), Gal-8 (N-terminal CRD), and Gal-3 
(138). In 2011, Öberg et al. reported the synthesis of a new family 
of talosamides with additional modifications at C2 and C3 with 
aromatic moieties. The best matches for these talosamide galectin 
inhibitors were found against Galectin-4C (C-terminal) (115): 
compound 18 (Table 3) presented a KD value of 94 μM and a good 
selectivity when compared to Gal-1 (1900 μM), Gal-2 (1700 μM), 
Gal-3 (570  μM), Gal-7 (>4000  μM), and Gal-9 (>4000  μM). 
These promising talose-based compounds still await detailed 
in vitro and in vivo evaluation.
Mimicking Glycans: Glycoamines on the Spot
A different approach to carbohydrate-based galectin inhibitors 
was proposed by Glinsky et  al., who showed that a synthetic 
β-galactoside-containing disaccharide-amino acid conjugate, the 
glycoamine lactulose-l-leucine (Lac-l-Leu, 19, Table  3), binds 
and inhibits Gal-3 by mimicking cancer-associated Tf antigen 
(Figure  1). This glycomimetic decreased the incidence of lung 
metastasis in human breast carcinoma xenografts (118) and also 
inhibited homotypic and heterotypic aggregation of prostate can-
cer cells via Gal-3 inhibition (81). Furthermore, intraperitoneal 
administration of Lac-l-Leu reduced bone metastasis of human 
prostate carcinoma cells in a mouse model (116). However, it 
required high concentrations (daily injections of 200 μL of Lac-
l-Leu 20 μM) to disrupt Gal-3–Tf interactions.
Further studies reported the design and synthesis of 
a new family of lactulose amines based on N-lactulose-
octamethylenediamine (LDO, 20, Table  3) (119). In order to 
assess multivalency as potential modification to increase local 
concentration of these galactose-containing ligands, N, N′-
dilactulose-octamethylenediamine (D-LDO, 21, Table 3) and N, 
N′-dilactulose-dodecamethylenediamine (D-LDD, 22; Table  3) 
were also synthesized. Compounds 10 and 11 (Table 3) exhib-
ited interesting regulatory effects in  vitro, such as prevention 
of Gal-1-mediated homotypic aggregation in melanoma cells 
and apoptosis of small cell lung carcinoma cells (119). In order 
to further develop these compounds and finally reach clinical 
status, additional structural studies clarifying the relevance of 
the aglycone moiety, and their selectivity even beyond galectins 
are required.
Does Size Matter? Polysaccharide-Derived 
Compounds
In addition to low-molecular weight carbohydrate-based syn-
thetic inhibitors, natural polysaccharides have also emerged as 
high affinity galectin inhibitors with low toxicity for cancer treat-
ment. Modified citrus pectin (MCP, Pectasol-C) and Davanat 
(GM-CT-01) are the best studied galectin blockers derived from 
natural sources.
Pectin-Based Compounds
Pectins compose a family of complex polysaccharides, which are 
found in high amounts in the plant primary wall. Three main 
pectic polysaccharides have been isolated from plant walls: 
homogalacturonan (HG), rhamnogalacturonan-I (RG-I), and 
substituted galacturonans (GS) (120). Pectins can be modified 
by pH and heat treatments, both of which expose galactoside 
residues by hydrolysis (139). The most studied modified pectin 
is MCP, which is obtained by partial degradation of citrus pectin 
polysaccharide chain and hydrolysis of the galacturonic acid 
esters from the HG regions. MCP through a multivalent display 
of galactoside residues has shown affinity for Gal-3 and has been 
tested as an anticancer agent in galectin-mediated tumorigenic 
processes (120).
The biological activity of MCP in cancer was extensively 
studied by Raz and coworkers (140–142). MCP has been shown 
to act as a ligand for Gal-3, while citrus pectin (CP) is unable 
to interact with this galectin (142). The authors showed that 
intravenous injection of MCP into mice bearing B16 melanoma 
resulted in significant decrease of lung colonization, while CP led 
to the opposite effect (142). In 2002, they expanded their findings 
to nude mice injected either with human breast carcinoma cells or 
with colon cancer cells, showing that the ability of MCP to inhibit 
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primary tumor growth and metastasis in vivo is not restricted to 
prostate cancer (140). The antitumor effects of MCP were associ-
ated with an antiangiogenic activity, since MCP also inhibited 
capillary tube formation in  vitro in human endothelial cells. 
Recently, Menachem et al. studied in vivo the combined inhibi-
tion of Ras and Gal-3 with FTS (S-trans farnesylthiosalicylic acid, 
Salirasib) and MCP, respectively, for the treatment of aggressive 
anaplastic thyroid carcinoma (143). Interestingly, FTS and MCP 
inhibited tumor growth in nude mice showing decreased levels of 
Gal-3, K-Ras-GTP, and p-ERK. However, the structure–function 
relationship of MCP and the molecular mechanisms underlying 
its effects are not yet completely understood, probably due to the 
lack of thorough structural characterization of pectin fractions. 
Nevertheless, MCP emerged as a very promising anticancer agent 
since it was the first reported inhibition of tumor growth by a 
soluble, orally ingested dietary carbohydrate fiber. In fact, two dif-
ferent commercial forms of MCP, PectaSol-C, and GCS-100, have 
been incorporated into clinical trials (112, 114, 115, 137, 138).
PectaSol (23, Table 3), and its most recent version Pectasol-C, 
commercial forms of MCP developed by EcoNugenics® (Santa 
Rosa, CA, USA), showed cytotoxic activity on different prostate 
cancer cell lines (122, 123). Additionally, Jiang et al. demonstrated 
that the combination of PectaSol-C with two polybotanical com-
pounds for breast and prostate health, BreastDefend (BD) and 
ProstaCaid (PC), synergistically inhibited metastatic phenotype 
of human breast and prostate cancer cell lines, respectively (121). 
In 2003, Guess and colleagues developed a Phase II clinical trial to 
investigate the tolerability and effect of PectaSol in patients with 
prostate cancer, showing that prostate cancer patients exhibited a 
serial increase in PSA after localized treatment (124). The results 
from this pilot clinical trial suggested that PectaSol may slow 
down PSA increase, as it improves prostate-specific antigen dou-
bling time (PSADT) in patients with recurrent prostate cancer. 
However, PSADT is an indirect measure of tumor progression 
and the detailed effect that PectaSol may have on prostate cancer 
progression is still poorly understood. Currently, there is an 
ongoing patient recruitment by EcoNugenics for a Phase III clini-
cal trial pointing at the effects of orally administered PectaSol-C 
for improving PSA kinetics in men with biochemical relapsed 
prostate cancer and serial increasing PSA (NCT: NCT01681823) 
(120).
GCS-100 (24, Table 3), another commercial MCP derivative, 
is also in clinical development for the treatment of cancer. GCS-
100 inhibits cell growth in various multiple myeloma cell lines 
(126). Demotte et al. showed that GCS-100 influences the rein-
vigoration of anergic TILs: treatment with GCS-100 successfully 
detached Gal-3 from CD8+ TILs and boosted cytotoxicity and 
secretion of proinflammatory cytokines (144). Furthermore, in 
tumor-bearing mice vaccinated with a tumor antigen, injections 
of GCS-100 led to increased tumor rejection compared to control 
mice, showing the potential application of pectin-derived agents 
in combination with therapeutic vaccination as a combined 
cancer treatment (145).
GCS-100 was evaluated as an anticancer agent in three clinical 
trials, but two of them were suspended because of lack of fund-
ing (NCT00776802 and NCT00609817). The third one (La Jolla 
Pharmaceutical Company, NCT00514696) was a Phase II study 
of the safety of GCS-100 in 24 subjects with chronic lymphocytic 
leukemia. GCS-100 was delivered intravenously, showing excel-
lent overall tolerability, partial remission in 25% of the patients 
and >50% shrinkage of lymph node lesions in 16% of patients 
(125, 146). Another interesting approach was reported by Zomer 
et al., who developed GR-MD-02 (25, Table 3), a pectin-derived 
galactoarabino-rhamnogalacturonan polysaccharide (127). 
GR-MD-02 is currently undergoing two clinical trials in com-
bination with immune checkpoints inhibitors: the anti-PD-1 
mAb Pembrolizumab and the anti-CTLA-4 mAb Ipilimumab 
for melanoma treatment (NCT02575404 and NCT02117362, 
respectively).
Galactomannan-Derived Compounds
Besides pectin-derived agents, β-d-(1  →  4)-galactomannan-
based compounds, such as GM-CT-01 (trade name DAVANAT, 26, 
Table 3), offer another alternative for galectin inhibition. GM-CT-
01 is isolated from seeds of Cyamopsis tetragonoloba (Guar gum), 
and subjected to a controlled partial chemical degradation (147). 
With an average size of 51 kDa, this β-d-(1 → 4)-galactomannan 
is composed by galactose residues α(1 → 6)-linked to the man-
nose backbone at recurring intervals (148). GM-CT-01 has been 
mainly tested as an allosteric inhibitor of Gal-1 (KD = 10 mM), 
but has also affinity for Gal-3, -7, and -9 (128, 149). GM-CT-01 
has been evaluated alone or in combination with the chemothera-
peutic agent 5-fluorouracil (5-FU) in preclinical studies. Phase I 
and II clinical studies for colon cancer treatment showed 70% 
higher stability for patients administered with GM-CT-01 and a 
46% increase in survival of patients with end stage colon cancer 
(NCT00110721) (128). This galectin inhibitor also influenced 
human TILs from patients with various cancers, boosting IFN-γ 
secretion upon ex vivo stimulation in ~80% of CD8+ TILs and 
~50% of CD4+ TILs (145). The response observed suggested that 
administration of GM-CT-01 may contribute to correct impaired 
TIL functions in cancer patients.
Peptides and Peptidomimetics
Peptides exhibit several advantages when compared to carbo-
hydrate-based ligands. While carbohydrate–lectin interactions 
occur in the mid-micromolar range, peptide–protein or protein–
protein interactions occur in the nanomolar range. Therefore, 
and since peptide synthesis has advanced considerably in the past 
few years, several research groups have developed an alternative 
approach using peptides or peptidomimetics to target galectins at 
their CRD or at distant sites.
In 2005, a pioneer work by Zou and colleagues reported 
binding of small peptides to Gal-3, with a concomitant reduc-
tion in cancer cell adhesion in  vitro (150). Considering that 
Tf glycoantigen (Figure 1) is exposed on up to 90% of human 
carcinomas (81) and is a major cancer cell surface carbohy-
drate ligand for Gal-3, the authors obtained synthetic peptides 
mimicking the Tf structure using combinatorial bacteriophage 
display technology. The most promising compounds, G3-A9 
(27, Table  3) and G3-C12 (28, Table  3), blocked interactions 
between Tf and Gal-3 and presented high affinity (72  nM) 
and good selectivity toward Gal-3 when compared to Gal-1, 
15
Cagnoni et al. Inhibition of Lectin–Glycan Interactions in Cancer
Frontiers in Oncology | www.frontiersin.org May 2016 | Volume 6 | Article 109
Gal-4, and LacNAc-binding plant lectins (123). These peptides 
effectively inhibited heterotopic adhesion of human breast 
carcinoma cells to endothelial cells, as well as homotypic tumor 
cell aggregation in  vitro. Some years later, these authors also 
reported the ability of peptide G3-C12 (28) to modulate tumor 
establishment and growth of human breast carcinoma cells in 
mice, demonstrating a significant reduction of lung metastatic 
tumors (72%) by in vivo bioluminiscent imaging (129). G3-C12 
(28, Table  3) was also studied in metastatic prostate cancer 
by Deutscher et  al., who proposed radiolabeled G3-C12 as a 
marker of Gal-3-expressing prostate tumors (130). 111In-labeled 
G3-C12 peptide showed good tumor uptake in severe combined 
immunodeficient (SCID) mice bearing human prostate tumor 
xenografts. A major limiting factor for its application in prostate 
tumor imaging was its non-specific uptake, as it was also found 
in kidneys. Yang et al. solved this issue by coupling G3-C12 to 
water-soluble N-(2-hydroxypropyl)methacrilamide (HPMA) 
copolymers as drug carriers (151). These copolymers were 
further modified either with 131I radioisotope for in vivo SPECT-
imaging (151), or with 5-FU for enhanced anticancer activity 
(152). 131I-G3-C12–HPMA copolymer showed higher tumor 
accumulation when compared to controls, although the authors 
experienced some difficulties with the adjustment of the ligand 
modification degree and the molecular size of the copolymer. 
On the other hand, 5-FU modified G3-C12–HPMA copolymer 
displayed a superior intracellular internalization followed by 
enhanced cytotoxicity and apoptosis induction in the PC-3 
tumor-bearing mouse model (152). Recently, Sun et al. reported 
that the conjugation of G3-C12–HPMA copolymer with doxo-
rubicin (G3-C12–HPMA–Dox) improved internalization into 
Gal-3-overexpressing PC-3 cells, but stimulated the transloca-
tion of Gal-3 to the mitochondria to prevent apoptosis (153). 
However, as time progressed, G3-C12–HPMA–Dox conjugates 
delivered increasing amounts of Dox into the mitochondria 
and overcame the anti-apoptotic effects of Gal-3. In spite of the 
lack of structural studies characterizing Gal-3/G3-C12 peptide 
binding, this peptide seems to be very promising not only as 
Gal-3-targeted imaging agent but also as therapeutic agent for 
Gal-3-overexpressing cancers such as melanoma and breast, 
ovarian, and gastric carcinomas (154).
Another example of peptide-based galectin ligand for cancer 
treatment is Anginex (29, Table  3), a 33-mer synthetic peptide 
originally designed to reproduce the β-sheet structure of antian-
giogenic proteins like platelet factor 4 (PF4), interleukin (IL)-8, 
and bactericidal/permeability-increasing protein (BPI) (155, 
156). This synthetic peptide has antiangiogenic and anti-tumor 
effects in vitro and in vivo (131, 157) and has been shown to bind 
Gal-1 (158), although it may also recognize other galectins such 
as Gal-2, -7, -8 (N-terminal), and -9 (N-terminal) (159). Later on, 
6DBF7 (30, Table 3), a partial peptidomimetic of Anginex, bearing 
a hydrophobic dibenzofuran scaffold required for the β-sheet pep-
tide configuration exhibited a better antiangiogenic performance 
in a mouse xenograft model of ovarian carcinoma (132).
In order to overcome the intrinsic susceptibility of peptides 
to hydrolysis by proteases, Dings et al. designed a non-peptidic 
topomimetic of Anginex and 6DBF7, based on a calixarene scaf-
fold (134). This compound, named calixarene 0118 or OTX008 
(31, Table  3), demonstrated potent angiogenesis inhibition in 
two mouse models of human ovarian carcinoma and murine 
melanoma. In addition, OTX008 has shown synergistic effects 
with sunitinib (a tyrosine kinase inhibitor) in ovarian carcinoma 
and glioblastoma mouse xenografts (133). Interestingly, OTX008 
downregulates cancer cell proliferation, invasion, and tumor 
angiogenesis in a variety of tumor cells (160) and is undergoing a 
Phase I clinical trial by OncoTx Inc. (NCT01724320) (161).
CONCLUSiON AND FUTURe 
PeRSPeCTiveS
In the past few years, the field of cancer therapy has experienced 
an impressive breakthrough with the development of targeted 
therapies and immune checkpoint blockers (162). However, 
although significant improvements have been achieved with these 
therapeutic agents, some patients have not shown clinical benefits, 
presumably because of the development of adaptive resistance 
mechanisms and acquisition of compensatory pathways.
Aberrant glycosylation has emerged as a hallmark of cancer 
progression, and the presence of a tumor-associated glycome is 
deeply associated with malignant transformation and metastasis-
associated processes including tumor cell migration, invasiveness, 
angiogenesis, and immune escape (14). However, the translational 
and clinical applications of altered glycan structures in cancer 
have not yet been completely accomplished, probably due to the 
complex regulation of the glycosylation machinery including 
glycosyltransferases and glycosidases. Heterogeneity is inherent 
to the language of glycans and crucial for their diverse biological 
roles as information carrier for lectins. On the other hand, lectins, 
glycan-binding receptors responsible for deciphering the glycome, 
arose as feasible targets for cancer therapy. As a result, consider-
able efforts have been made to disrupt glycan–lectin interactions 
by designing pharmacological anticancer agents that target dif-
ferent lectins including selectins, siglecs, and galectins. Further 
studies are still necessary to understand the precise underlying 
mechanisms of the antitumor effects displayed by lectin block-
ers, and to explore the potential complementation or synergy of 
turning-off lectin signaling with immune checkpoint blockade 
therapies, targeted therapies (e.g., small molecule inhibitors of 
receptor tyrosine kinases) and antiangiogenic therapies, as well as 
with chemotherapy, radiotherapy, and vaccination strategies. As 
of today, different approaches have generated chemical inhibitors 
for lectin–glycan interactions, resulting in diverse selectivity, 
affinity, and therapeutic efficacy in cancer models.
Small glycan derivatives and glycomimetics, which repre-
sent the majority of lectin blockers reported to date, target 
the carbohydrate-binding site and showed promising affinities 
and lectin selectivity in  vitro. However, these carbohydrate-
based ligands suffer certain disadvantages for their use in the 
clinics, i.e., low in vivo bioavailability, susceptibility to glycosi-
dase hydrolysis, and fast clearance. For instance, for galectin 
inhibition, no galactose-based ligand has reached clinical tri-
als up to date. Thus, alternative approaches have been made to 
circumvent these drawbacks including the design of hydrolyti-
cally stable N-, S-, and C-saccharides and the development of 
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neoglycoproteins with higher bioavailability (163), but only a 
few of them have been successfully tested in vivo. Although not 
included in this review, metabolic inhibitors for sugar nucleo-
tide biosynthesis were also proposed and efficiently tested: for 
example, per-acetylated 4-fluoro-glucosamine (4-F-GlcNAc) 
as a GlcNAc biosynthetic inhibitor was evaluated in cancer 
melanoma- or lymphoma-bearing mice, showing enhanced 
tumor lymphocytic infiltration and increased the frequency 
of cytotoxic T cells and IFN-γ production (164). However, 
these chemical inhibitors do not affect protein glycosylation in 
a specific way. Therefore, small carbohydrate inhibitors have 
to face diverse intrinsic drawbacks before reaching clinical 
settings.
Multivalent display by polysaccharide inhibitors has become an 
interesting approach for galectin and selectin inhibition. Heparin, 
dextran, and chitosan sulfated derivatives have been successfully 
tested as selectin inhibitors. Nevertheless, no detailed clinical trials 
have been yet designed to determine the antimetastatic effects of 
heparin derivatives in cancer. On the other hand, galactomannan-
derived compounds, together with pectin-derived agents, are 
probably the most successful galectin chemical inhibitors that 
reached clinical evaluation in cancer patients. DAVANAT, GCS-
100, and PectaSol currently being tested in clinical trials (among 
several other polysaccharides-based inhibitors) seem very prom-
ising anticancer agents, since they present high-binding affinities 
and can easily be obtained from natural sources. Moreover, 
these ligands stress the importance that dietary carbohydrate 
compounds may reach as therapeutic agents. Looking to the 
future, critical structure–function relationships and selectivity 
studies are still necessary, as well as elucidation of the precise 
mechanisms underlying interactions with these polysaccharide 
compounds. For example, the use of MCP as an anticancer agent 
is still limited because of lack of selectivity and structure vari-
ability (165). In fact, there are multiple MCPs on the market with 
different molecular weight range, diverse esterification degrees, 
and limited characterization at the molecular level. Although the 
affinity of MCPs for Gal-3 has been documented, there is still 
no study showing selectivity with regard to other lectins. In fact, 
MCP demonstrated the ability to detach cell surface binding of 
Gal-1 and Gal-3 to melanoma cells at comparable concentrations 
(144). In order to completely understand the biological modes 
of action of MCPs as well as other polysaccharide-based ligands 
in cancer-related processes, further studies are required to assess 
their affinity toward other lectins.
As alternative inhibitors, peptides and peptidomimetics have 
emerged as interesting agents capable of overcoming some of 
the intrinsic disadvantages of glycans. Among them, fluorinated 
C-manno-peptides represent promising therapeutic agents as 
selectin inhibitors, while G3-C12 (28) and the Anginex-derivative 
OTX008 (31) represent the most successful approaches for inhi-
bition of Gal-3 and Gal-1, respectively; both are currently being 
tested in clinical trials.
With the advances in molecular biology and immunology, 
anti-sense nucleotides, mAbs, and lectin modifications have 
also been proposed as potential strategies for lectin inhibition. 
Small-interfering RNA (siRNA) has recently been offered as an 
alternative approach for galectin inhibition, but literature is still 
limited. In a recent study, Park et al. demonstrated that siRNA-
mediated silencing of Gal-3 in a human osteosarcoma cell line 
resulted in decreased tumor cell migration and invasiveness (84). 
On the other hand, anti-E-selectin and anti-L-selectin mAbs have 
been successfully tested in the treatment of liver metastasis and 
ovarian cancer, respectively (49, 166, 167). In addition, modifica-
tions of natural selectin ligands such as P-selectin Glycoprotein 
Ligand-1 (PSGL-1) (i.e., by conjugation with IgG) afforded an 
auspicious selective inhibitor for interrupting leukocyte rolling 
and adhesion (168). In the case of galectin-inhibition, availability 
of recombinant proteins (i.e., truncated form of Gal-3) as well 
as mAbs (i.e., F8.G7 for Gal-1) opened new avenues for more 
specific and efficient blockers (34, 169–171). These therapies have 
been successfully tested in vivo and demonstrated a very good 
performance, suggesting their potential translation to clinical 
trials.
In summary, the data presented in this article stress the 
importance of understanding the biochemistry, biology, and gly-
cobiology involved in tumor development and progression. The 
current major challenge faced by this field is designing selective 
inhibitors of lectin–glycan interactions with increased bioavail-
ability. In turn, combined therapies of chemical inhibitors with 
biological therapeutics may tailor cancer treatments according to 
the unique features of individual tumors and patients.
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